News & Blogs

Commitment to Seniors Opposes Draft Regulations Under the Comprehensive Outbound Investment National Security (COINS) Act

Washington, D.C. – October 22, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the U.S. Treasury Department’s draft regulations under the Comprehensive Outbound Investment National Security (COINS) Act, which would expand restrictions on outbound investment in biopharmaceuticals. American seniors have the most to lose when government policies stand in the way of medical progress. Treasury’s proposed expansion of investment restrictions threatens to do exactly that. By preventing American companies from pursuing…

Learn More

Update on Foreign Freeloading on American Drug Innovation

The U.S. is the global leader of biomedical innovation, and other nations are not paying their fair share for America’s groundbreaking research and development. Other rich countries use government price controls to limit their spending on brand drugs. President Trump has urged these countries to end the freeloading and start investing. While the U.K. answered the call and agreed to pay more for US brand drugs, other nations, including France, Germany, and Japan, are doubling…

Learn More

Beware the Post-Midterm Price Control Creep

Storm clouds are gathering for Republicans ahead of next month’s midterm elections. If the forecast holds, a divided government could leave Washington gridlocked for two years. Yet one policy idea being floated on Capitol Hill may find support from both congressional Democrats and the White House during the stalemate. For those who favor limited government and competitive markets, the prospect is unnerving. In 2022, President Joe Biden and his allies in Congress passed the Inflation…

Learn More

Buyer Beware: New Medicare Plans Have Fewer Benefits, Higher Costs

It is going to be a tough year for seniors shopping for Medicare coverage. If you don’t choose wisely, you might get hit with surprise bills for your medications, or learn too late that your doctors are out of network. For the third year in a row, major Medicare insurers are pruning some benefits while adding bigger out-of-pocket charges such as deductibles. “Medicare Advantage plans are leaning toward focusing on margin repair,” said Michael Ha,…

Learn More

How MFN pricing in the final GLOBE Model will affect beneficiary OOP costs

Avalere Health’s recently updated analysis of 2023 Medicare Current Beneficiary Survey data suggests that the Global Benchmark for Efficient Drug Pricing (GLOBE) Model would have a very limited impact on OOP costs. We found that: Among fee-for-service (FFS) beneficiaries who used GLOBE-eligible drugs, less than 3,000 have standard Part B OOP cost-sharing exposure because they do not have supplemental insurance. When accounting for the GLOBE Model’s application to approximately 25% of Part B FFS beneficiaries,…

Learn More

Most Favored Nation Price Controls Disfavor Patients

President Trump recently boasted that all 50 state Medicaid programs, along with the DC and Puerto Rico programs, are now using Most Favored Drug (MFN) pricing. MFN pricing requires pharmaceutical companies to charge American consumers a price equal to or below the lowest price they charge one of 19 reference countries. MFN is a response to the longstanding complaint that Americans pay more for pharmaceuticals made by American companies than consumers in other countries. One…

Learn More

Commitment to Seniors Opposes CMMI’s Final Rule for GLOBE Drug Pricing Model

Washington, D.C. – October 1, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the final rule for the Global Benchmark for Efficient Drug Pricing (GLOBE) model from the Centers for Medicare and Medicaid Innovation (CMMI). This model effectively imposes price controls on the American health care market by tying U.S. drug prices to prices set by foreign governments. Importing foreign price controls risks American jobs, undermines U.S. leadership in pharmaceutical innovation,…

Learn More

Emulating European healthcare won’t win America the biotech race

As Washington debates new ways to make the nation’s healthcare system work better for Americans, policymakers should keep one question in mind: What would happen if the U.S. stopped being the world’s most attractive place to discover and develop new medicines? The answer is not theoretical. Europe already ran that experiment. For decades, the United States has been the global leader in medical innovation. American researchers, universities, investors and life sciences companies have produced treatments…

Learn More